Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for High-grade serous ovarian cancer, drawn from the whole corpus: 17 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No screening test lowers mortality.
Homologous recombination proficient tumours gain little from PARP inhibitors.
Platinum-resistant disease remains largely incurable.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Access to HRD testing and PARP inhibitors outside high-income countries.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
Objective responses in about a third of patients with folate receptor alpha-high platinum-resistant ovarian cancer; accelerated approval in November 2022.
A milestone in how this cancer is treated.
OS 53.
PFS HR 0.
PFS HR 0.